Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Core Insights - AnaptysBio, Inc. announced that its investigational drug ANB032 did not meet primary and secondary endpoints in the ARISE-AD trial for moderate-to-severe atopic dermatitis, leading to the decision to discontinue further investment in this asset [1][2][3] - The company plans to focus resources on its autoimmune portfolio, particularly on rosnilimab, which targets PD-1+ T cells, with upcoming data releases anticipated in early 2025 and 2026 [2][7] - AnaptysBio reported a year-end 2024 cash balance of approximately $415 million, extending its cash runway guidance through the end of 2027, excluding potential milestones and royalties from GSK [1][2] Study Details - The ARISE-AD study involved 201 patients with a mean baseline EASI score of 27.3, randomized to receive different doses of ANB032 or placebo over 12 weeks [2][3] - ANB032 was well tolerated across all doses, with no safety signals observed, although it did not achieve the primary endpoint of EASI-75 improvement [3][5] - The study noted higher placebo response rates than historical norms, particularly in the U.S., despite some durable off-drug responses observed in patients treated with ANB032 [4][5] Future Developments - AnaptysBio anticipates sharing top-line Phase 2b data for rosnilimab in rheumatoid arthritis in February 2025, followed by Phase 2 data for ulcerative colitis in Q1 2026 [2][7] - The company is also advancing other programs, including ANB033 and ANB101, with ANB033 currently in Phase 1 trials [7]